Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis.

Chronic neutrophilic airway inflammation is an important feature of cystic fibrosis (CF). Noninvasive inflammatory markers may be useful in monitoring CF. Leukotriene B4 (LTB4) and interleukin (IL)-6 are inflammatory mediators that are increased in chronic neutrophilic inflammation. The aim of this study was to assess whether LTB4 and IL-6 were increased in exhaled breath condensate of CF patients and whether they could be used to monitor inflammation. Twenty patients with CF (13 males, age of 28 +/- 9 years) were recruited together with 15 age-matched healthy subjects (8 males, age 35 +/- 7 years). LTB4 and IL-6 levels were markedly elevated in patients with acute exacerbations (28.8 +/- 4.3 and 8.7 +/- 0.4 pg/ml) compared with control subjects (6.8 +/- 0.7 and 2.6 +/- 0.1 pg/ml, p < 0.0001). We also observed a decrease of exhaled LTB4 and IL-6 concentrations after antibiotic treatment in six patients who were followed until clinically stable (31.1 +/- 4.4 and 9.5 +/- 0.4 pg/ml vs. 18.8 +/- 0.8 and 6.4 +/- 0.2 pg/ml, respectively) and an increase in 15 CF patients infected with Pseudomonas aeruginosa (34.3 +/- 5.0 and 9.3 +/- 0.3 pg/m) compared with those infected with other bacteria (18.3 +/- 0.7 and 6.9 +/- 0.5 pg/ml). These findings suggest that LTB4 and IL-6 levels are increased in exhaled breath condensate of patients with CF during exacerbation and could be used to monitor airway inflammation in these patients.

[1]  B. Strandvik,et al.  Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Zakrzewski,et al.  Detection of sputum eicosanoids in cystic fibrosis and in normal saliva by bioassay and radioimmunoassay. , 1987, British journal of clinical pharmacology.

[3]  M. Berger.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? , 1991, Clinical reviews in allergy.

[4]  C. P. Green,et al.  Sputum cysteinyl‐leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosis , 1992, Pediatric pulmonology.

[5]  M. Konstan,et al.  Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis. , 1993, The American review of respiratory disease.

[6]  Kwang Woo Kim,et al.  Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. , 1995, The Journal of allergy and clinical immunology.

[7]  R. Heuertz,et al.  Peptides derived from C-reactive protein inhibit neutrophil alveolitis. , 1996, Journal of immunology.

[8]  T. Noah,et al.  Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. , 1997, The Journal of infectious diseases.

[9]  F. Ratjen,et al.  Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis , 1997, Pediatric pulmonology.

[10]  G. Mancuso,et al.  Porins of Pseudomonas aeruginosa induce release of tumor necrosis factor alpha and interleukin-6 by human leukocytes , 1997, Infection and immunity.

[11]  H. Tilg,et al.  IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. , 1997, Immunology today.

[12]  C. Cross,et al.  Oxidative stress in cystic fibrosis: does it occur and does it matter? , 1997, Advances in pharmacology.

[13]  J. Elborn,et al.  Circulating immunoreactive interleukin-6 in cystic fibrosis. , 1998, American journal of respiratory and critical care medicine.

[14]  M. Grisham,et al.  Superoxide released from neutrophils causes a reduction in nitric oxide gas. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[15]  P. Montuschi,et al.  Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. , 1999, American journal of respiratory and critical care medicine.

[16]  W. Hop,et al.  Hydrogen peroxide and nitric oxide in exhaled air of children with cystic fibrosis during antibiotic treatment. , 2000, The European respiratory journal.

[17]  P. Barnes,et al.  Increase in exhaled carbon monoxide during exacerbations of cystic fibrosis , 2000, Thorax.

[18]  J. Govan,et al.  Endotoxic activity of lipopolysaccharides isolated from emergent potential cystic fibrosis pathogens. , 2000, FEMS immunology and medical microbiology.

[19]  P. Shah,et al.  Exhaled ethane is elevated in cystic fibrosis and correlates with carbon monoxide levels and airway obstruction. , 2000, American journal of respiratory and critical care medicine.

[20]  V. Deretic,et al.  Innate Lung Defenses and Compromised Pseudomonas aeruginosa Clearance in the Malnourished Mouse Model of Respiratory Infections in Cystic Fibrosis , 2000, Infection and Immunity.

[21]  P. Barnes,et al.  Nasal and exhaled nitric oxide is reduced in adult patients with cystic fibrosis and does not correlate with cystic fibrosis genotype. , 2000, Chest.

[22]  B. Erokwu,et al.  Effect of Pseudomonas infection on weight loss, lung mechanics, and cytokines in mice. , 2000, American journal of respiratory and critical care medicine.

[23]  T. Shimizu,et al.  Leukotriene B4: metabolism and signal transduction. , 2001, Archives of biochemistry and biophysics.

[24]  D. Geddes,et al.  Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence. , 2001, The European respiratory journal.

[25]  F. Accurso,et al.  Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction. , 2001, American journal of respiratory and critical care medicine.

[26]  P. Shah,et al.  Increased nitrotyrosine in exhaled breath condensate in cystic fibrosis. , 2001, The European respiratory journal.

[27]  P. Barnes,et al.  Exhaled markers of pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[28]  P. Barnes,et al.  Exhaled markers of inflammation , 2001, Current opinion in allergy and clinical immunology.